1
|
Hou H, Liu X, Liu J, Wang Y. Carbohydrate polymer-based nanoparticles with cell membrane camouflage for cancer therapy: A review. Int J Biol Macromol 2025; 289:138620. [PMID: 39674458 DOI: 10.1016/j.ijbiomac.2024.138620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Revised: 11/21/2024] [Accepted: 12/08/2024] [Indexed: 12/16/2024]
Abstract
Recent developments in biomimetic nanoparticles, specifically carbohydrate polymer-coated cell membrane nanoparticles, have demonstrated considerable promise in treating cancer. These systems improve drug delivery by imitating natural cell actions, enhancing biocompatibility, and decreasing immune clearance. Conventional drug delivery methods frequently face challenges with non-specific dispersal and immune detection, which can hinder their efficiency and safety. These biomimetic nanoparticles improve target specificity, retention times, and therapeutic efficiency by using biological components like chitosan, hyaluronic acid, and alginate. Chitosan-based nanoparticles, which come from polysaccharides found in nature, have self-assembly abilities that make them better drug carriers. Hyaluronic acid helps target tissues more effectively, especially in cancer environments where there are high levels of hyaluronic acid receptors. Alginate-based systems also enhance drug delivery by being biocompatible and degradable, making them ideal choices for advanced therapeutic uses. Moreover, these particles hold potential for overcoming resistance to multiple drugs and boosting the body's immune reaction to tumors through precise delivery and decreased side effects of chemotherapy drugs. This review delves into the possibilities of using carbohydrate polymer-functionalized nanoparticles and their impact on enhancing the efficacy of cancer treatment.
Collapse
Affiliation(s)
- Haijia Hou
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - Xuejian Liu
- Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China
| | - Jun Liu
- Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
| | - Yudong Wang
- Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
| |
Collapse
|
2
|
Ryabchikova MN, Nelyubin AV, Klyukin IN, Selivanov NA, Bykov AY, Kubasov AS, Skribitsky VA, Finogenova YA, Shpakova KE, Kasianov AA, Lipengolts AA, Zhdanov AP, Grigoreva EY, Zhizhin KY, Kuznetsov NT. Synthesis of New Promising BNCT Agents Based on Conjugates of closo-Dodecaborate Anion and Aliphatic Diamino Acids. Int J Mol Sci 2024; 26:68. [PMID: 39795927 PMCID: PMC11719580 DOI: 10.3390/ijms26010068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 12/13/2024] [Accepted: 12/20/2024] [Indexed: 01/13/2025] Open
Abstract
In this work, a series of boronated amidines based on the closo-dodecaborate anion and amino acids containing an amino group in the side chain of the general formula [B12H11NHC(NH(CH2)nCH(NH3)COOH)CH3], where n = 2, 3, 4, were synthesized. These derivatives contain conserved α-amino and α-carboxyl groups recognized by the binding centers of the large neutral amino acid transporter (LAT) system, which serves as a target for the clinically applied BNCT agent para-boronophenylalanine (BPA). The paper describes several approaches to synthesizing the target compounds, their acute toxicity studies, and tumor uptake studies in vivo in two tumor models. The promising compound [B12H11NHC(NH(CH2)2CH(NH3)COOH)CH3]*3H2O demonstrates low toxicity (LD50 in a range from 150 to 300 mg/kg) and excellent solubility and also shows selective uptake in experimental melanoma in laboratory mice (T/N ratio remained >3 up to 60 min post-injection, with a maximum T/N of 6.2 ± 2.8 at 45 min).
Collapse
Affiliation(s)
| | - Alexey V. Nelyubin
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Ilya N. Klyukin
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Nikita A. Selivanov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Alexander Yu. Bykov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Alexey S. Kubasov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Vsevolod A. Skribitsky
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
- Engineer and Physics Institute of Biomedicine, National Research Nuclear University “MEPhI”, 31, Kashirskoe Shosse, 115409 Moscow, Russia
| | - Yulia A. Finogenova
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
| | - Kristina E. Shpakova
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
- Engineer and Physics Institute of Biomedicine, National Research Nuclear University “MEPhI”, 31, Kashirskoe Shosse, 115409 Moscow, Russia
| | - Anton A. Kasianov
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
- Engineer and Physics Institute of Biomedicine, National Research Nuclear University “MEPhI”, 31, Kashirskoe Shosse, 115409 Moscow, Russia
| | - Alexey A. Lipengolts
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
- Engineer and Physics Institute of Biomedicine, National Research Nuclear University “MEPhI”, 31, Kashirskoe Shosse, 115409 Moscow, Russia
| | - Andrey P. Zhdanov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Elena Yu. Grigoreva
- N.N. Blokhin National Medical Research Center of Oncology, 24, Kashirskoe Shosse, 115522 Moscow, Russia; (Y.A.F.); (A.A.K.); (E.Y.G.)
| | - Konstantin Yu. Zhizhin
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| | - Nikolay T. Kuznetsov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia; (A.V.N.); (I.N.K.); (N.A.S.); (A.Y.B.); (A.S.K.); (V.A.S.); (K.E.S.); (A.A.L.); (K.Y.Z.); (N.T.K.)
| |
Collapse
|
3
|
Zhang Y, Zhang Q, Li C, Zhou Z, Lei H, Liu M, Zhang D. Advances in cell membrane-based biomimetic nanodelivery systems for natural products. Drug Deliv 2024; 31:2361169. [PMID: 38828914 PMCID: PMC11149581 DOI: 10.1080/10717544.2024.2361169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 05/14/2024] [Indexed: 06/05/2024] Open
Abstract
Active components of natural products, which include paclitaxel, curcumin, gambogic acid, resveratrol, triptolide and celastrol, have promising anti-inflammatory, antitumor, anti-oxidant, and other pharmacological activities. However, their clinical application is limited due to low solubility, instability, low bioavailability, rapid metabolism, short half-life, and strong off-target toxicity. To overcome these drawbacks, cell membrane-based biomimetic nanosystems have emerged that avoid clearance by the immune system, enhance targeting, and prolong drug circulation, while also improving drug solubility and bioavailability, enhancing drug efficacy, and reducing side effects. This review summarizes recent advances in the preparation and coating of cell membrane-coated biomimetic nanosystems and in their applications to disease for targeted natural products delivery. Current challenges, limitations, and prospects in this field are also discussed, providing a research basis for the development of multifunctional biomimetic nanosystems for natural products.
Collapse
Affiliation(s)
- Yifeng Zhang
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Qian Zhang
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Chunhong Li
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Ziyun Zhou
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Hui Lei
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Minghua Liu
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| | - Dan Zhang
- School of Pharmacy, Southwest Medical University, Luzhou, P. R. China
| |
Collapse
|
4
|
Kong W, Wang C, Wang H, Liu H, Mu J, Jiang J, Zhang C. Hyperosmotic cold shock mouse melanoma cells encapsulated with doxorubicin for targeted treatment of melanoma. Front Oncol 2024; 14:1403719. [PMID: 38751816 PMCID: PMC11094257 DOI: 10.3389/fonc.2024.1403719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 04/15/2024] [Indexed: 05/18/2024] Open
Abstract
Background The primary treatment strategies for melanoma include surgical excision, chemotherapy, and radiotherapy. However, the efficacy of these treatments is often limited by drug resistance, recurrence, and severe side effects. Therefore, we aimed to develop a targeted drug delivery system capable of selectively locating tumor sites to minimize systemic toxicity and enhance therapeutic efficacy. This cell drug delivery system can also deliver chemotherapeutic drugs to the tumor microenvironment. Methods We treated B16F10 cells with hyperosmotic cold shock (HCS) to obtain and characterize HCS cells. We then investigated the anti-tumor effects and immune activation capabilities of these cells and explored their potential as a targeted drug delivery system. Results HCS cells not only maintained an intact cellular structure and tumor antigens but also exhibited high expression of the homologous melanoma-associated antigen glycoprotein 100. These cells demonstrated an exceptional capacity for loading and releasing doxorubicin, which has chemotherapeutic anti-tumor effects. HCS cells can precisely target the tumor microenvironment to minimize systemic toxicity, inducing an immune response by activating CD3+ and CD4+ T cells. Conclusion HCS cells are non-carcinogenic, with both cellular and tumor antigens intact; thus, they are suitable drug delivery carriers. Our findings highlight the potential of HCS cells for carrying doxorubicin because of their high drug-loading efficiency, effective tumor-targeting and anti-tumor effects. Therefore, our results will facilitate the development of melanoma treatments that have higher efficacy than those in the literature.
Collapse
Affiliation(s)
- Weihui Kong
- Department of Stomatology, The First Hospital of Jilin University, Changchun, China
| | - Chengran Wang
- Scientific Research Center, China-Japan Union Hospital, Jilin University, Changchun, China
| | - Hui Wang
- Scientific Research Center, China-Japan Union Hospital, Jilin University, Changchun, China
| | - Haiou Liu
- Department of Stomatology, The First Hospital of Jilin University, Changchun, China
| | - Jianhui Mu
- Spine Surgery, China-Japan Union Hospital, Jilin University, Changchun, China
| | - Jinlan Jiang
- Scientific Research Center, China-Japan Union Hospital, Jilin University, Changchun, China
| | - Congxiao Zhang
- Department of Stomatology, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
5
|
Mohsin MH, Khashan KS, Sulaiman GM, Mohammed HA, Qureshi KA, Aspatwar A. A novel facile synthesis of metal nitride@metal oxide (BN/Gd 2O 3) nanocomposite and their antibacterial and anticancer activities. Sci Rep 2023; 13:22749. [PMID: 38123673 PMCID: PMC10733422 DOI: 10.1038/s41598-023-49895-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 12/13/2023] [Indexed: 12/23/2023] Open
Abstract
In this study, a novel core/shell nanocomposite structure (h-BN@Gd2O3 NCs) was created for the first time by combining hexagonal boron nitride (h-BN) with doped gadolinium oxide (Gd2O3) using different laser pulse numbers, i.e., 150, 338, and 772 pulses. We employed various analytical techniques, including mapping analysis, FE-SEM, EDS, HRTEM, SAED, XRD, zeta potential analysis, DLS, FTIR, Raman spectroscopy, and PL measurements, to characterize the synthesized h-BN, c-Gd2O3, and h-BN@Gd2O3 NCs (338 pulses). XRD results indicated hexagonal and cubic crystal structures for BN and Gd2O3, respectively, while EDS confirmed their chemical composition and elemental mapping. Chemical bonds between B-N-Gd, B-N-O, and Gd-O bands at 412, 455, 474, and 520 cm-1 were identified by FTIR analysis. The antimicrobial and anticancer activities of these NCs using agar well diffusion and MTT assays. They exhibited potent antibacterial properties against both Gram-positive and Gram-negative pathogens. Furthermore, NCs have reduced the proliferation of cancerous cells, i.e., human colon adenocarcinoma cells (HT-29) and human breast cancer cells (MCF-7), while not affecting the proliferation of the normal breast cell line (MCF-10). The anticancer efficacy of NCs was validated by the AO/EtBr assay, which confirmed apoptotic cell death. Blood compatibility on human erythrocytes was also confirmed by hemolytic and in vitro toxicity assessments. The compiled results of the study proposed these nanoparticles could be used as a promising drug delivery system and potentially in healthcare applications.
Collapse
Affiliation(s)
- Mayyadah H Mohsin
- Department of Applied Sciences, University of Technology, Baghdad, Iraq
| | - Khawla S Khashan
- Department of Applied Sciences, University of Technology, Baghdad, Iraq
| | - Ghassan M Sulaiman
- Department of Applied Sciences, University of Technology, Baghdad, Iraq.
| | - Hamdoon A Mohammed
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, 51452, Qassim, Saudi Arabia
- Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo, 11884, Egypt
| | - Kamal A Qureshi
- Faculty of Medicine and Health Technology, Tampere University, 33520, Tampere, Finland
| | - Ashok Aspatwar
- Faculty of Medicine and Health Technology, Tampere University, 33520, Tampere, Finland.
| |
Collapse
|